Syneos Health, Fosun Pharma USA Partner to Launch Serplulimab

HEALTHCARE

For the launch of Serplulimab, a novel anti-PD-1 antibody for extensive stage small cell lung cancer in the United States, Syneos Health, the only fully integrated biopharmaceutical solutions organization, has announced a strategic partnership with Fosun Pharma USA Inc., the US-based subsidiary of Shanghai Fosun Pharmaceutical Co., Ltd. Syneos Health will provide Full-Service Commercial support through its Syneos One team as part of the partnership.

Shanghai Henlius Biotech, Inc. created the first novel monoclonal antibody, and Fosun Pharma USA is the only company authorized to sell Serplulimab in the United States once regulatory approval is granted. As the first asset in the partnership with Syneos Health, Serplulimab has the potential to be the first anti-PD-1 mAb for the first-line treatment of SCLC.

It is anticipated that the partnership between the two businesses will continue to grow, utilizing Syneos One’s complete commercial infrastructure and expert product development team to support Fosun Pharma USA’s expansion.

See also  US FDA Planning to Allow Clinical Trials of Pig Organ Transplant

According to Lee Taurman, EVP, Global Head, Syneos One, Syneos Health, their capacity to supply appropriate solutions that span the entire product development cycle is demonstrated by this partnership, and their ability to strategize and execute across multiple service lines, including medical affairs and commercial, makes them the premier partner for Fosun Pharma USA.

Lee Taurman added that, they are effectively optimizing Fosun Pharma’s asset portfolio as they expand their Innovative Medicine business in the United States and providing the company with strategic support as its portfolio changes.

Rong Yang, CEO and Senior Vice President of Fosun Pharma USA, stated that Fosun Pharma is pleased to have Syneos Health as their strategic partner as the company expands its innovative medicine presence in the United States.

Rong Yang added that serplulimab is their first novel medicine and is currently in the final bridging study stage in the United States for the indication of ES-SCLC. After regulatory approval, they anticipate partnering with Syneos Health to provide the product to patients in the United States.

See also  Pfizer and Valneva Begins Phase 3 Trial of Lyme Disease Vaccine

Mousumi Sannigrahi, Fosun Pharma USA’s SVP and Head of Commercial, Innovative Medicine, stated, “We are excited about the partnership with Syneos Health and working together to build an innovative commercialization model to best serve our healthcare professionals and patients in the changing environment of today.”

In particular, Syneos Health will provide Fosun with staffing and capabilities in Medical Affairs, Market Access, Marketing, Sales, and Operations for Serplulimab in order to assist Fosun in bringing new products to market and filling important unmet patient needs.